| 1721 |
LUCIENA |
ENASIDEBIB 50 MG |
TABLET |
BOTTLE |
TREATMENT OF ADULTS PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA WITH IDH2 MUTATION |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
09 L 1019/23 |
26-SEP-2023 |
25-SEP-2026 |
View |
| 1722 |
LUCIENCOR |
ENCORAFENIB 75 MG |
CAPSULE |
BOTTLE |
IN COMBINATION WITH BINIMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH A BRAF V600E OR V600K MUTATION |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
08 L 1184/24 |
22-AUG-2024 |
21-AUG-2027 |
View |
| 1723 |
LUCIENTRE |
ENTRECTINIB 100 MG |
TABLET |
BOTTLE |
ADULT PATIENT WITH ROS1-POSITIVE METASTATIC NON SMALL CELL LUNG CANCER AS DETECTED BY AN FDA APPROVED TEST |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
03 L 1075/24 |
14-MAR-2023 |
13-MAR-2027 |
View |
| 1724 |
LUCIENTRE |
ENTRECTINIB 200 MG |
CAPSULE |
BOTTLE |
ADULT PATIENT WITH ROS1-POSITIVE METASTATIC NON SMALL CELL LUNG CANCER AS DETECTED BY AN FDA APPROVED TEST |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
12 L 1279/24 |
03-FEB-2025 |
02-FEB-2030 |
View |
| 1725 |
LUCIERDA |
ERDAFITINIB 3 MG |
TABLET |
BOTTLE |
FOR THE TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT HAS SUSCEPTIBLE FGFR3 OR FGFR2 GENETIC ALTERATION |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
02 L 1067/24 |
14-MAR-2023 |
13-MAR-2027 |
View |
| 1726 |
LUCIERDA |
ERDAFITINIB 4 MG |
TABLET |
BOTTLE |
FOR THE TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT HAS SUSCEPTIBLE FGFR3 OR FGFR2 GENETIC ALTERATION |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
02 L 1068/24 |
14-MAR-2023 |
13-MAR-2027 |
View |
| 1727 |
LUCIERDA |
ERDAFITINIB 5 MG |
TABLET |
BOTTLE |
FOR THE TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT HAS SUSCEPTIBLE FGFR3 OR FGFR2 GENETIC ALTERATION |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
02 L 1069/24 |
14-MAR-2023 |
13-MAR-2027 |
View |
| 1728 |
LUCIERLO |
ERLOTINIB 150 MG |
TABLET |
BOTTLE |
FOR TREATMENT OF PATIENTS WITH METASTATIC NON SMALL CELL LUNG CANCER WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR EXON 19 DELETIONS OR EXON 21 SUBSTITUTION MUTATIONS |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
09 L 1214/24 |
31-OCT-2024 |
30-OCT-2029 |
View |
| 1729 |
LUCIEVER |
EVEROLIMUS 10 MG |
TABLET |
BLISTERPACK |
FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED HORMONE RCEPTOR-POSITIVE, HER2S-NEGATIVE BREAST CANCER IN COMBINATION WITH EXEMESTANE AFTER FAILURE OF TREATMENT WITH LETREOZOLE OR ANSTROZOLE, ADULT WITH ADVANCED RENAL CELL CARCINOMA AFTER FAILURE OF TREATMENT WITH SUNITINIB OR SORAFENIB, ADULT WITH RENAL ANGIOMYOLIPOMA AND TUBERCULOSIS SCLEROSIS COMPLEX, NOT REQUIRING IMMEDIATE SURGERY |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
02 L 1301/25 |
25-FEB-2025 |
24-FEB-2030 |
View |
| 1730 |
LUCIEVER |
EVEROLIMUS 5 MG |
TABLET |
BLISTERPACK |
FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED HORMONE RCEPTOR-POSITIVE, HER2S-NEGATIVE BREAST CANCER IN COMBINATION WITH EXEMESTANE AFTER FAILURE OF TREATMENT WITH LETREOZOLE OR ANSTROZOLE, ADULT WITH ADVANCED RENAL CELL CARCINOMA AFTER FAILURE OF TREATMENT WITH SUNITINIB OR SORAFENIB, ADULT WITH RENAL ANGIOMYOLIPOMA AND TUBERCULOSIS SCLEROSIS COMPLEX, NOT REQUIRING IMMEDIATE SURGERY |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
02 L 1303/25 |
25-FEB-2025 |
24-FEB-2030 |
View |
